SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Onureg

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. (since September 2020) and EU (since June 2021).
Why 3/10
Onureg is already approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next ~12 months. It is a minor product within BMS's diversified ~$50B revenue portfolio, grouped under "Other Growth Brands" without individually reported revenue. ImpactScore is 3 per the rubric: an approved, marketed drug with no imminent binary catalyst.
Actionable Insight NEUTRAL

Onureg is already approved and marketed with no pending regulatory decision. The next catalysts to watch are data readouts from ongoing early-stage combination trials (CC-486 with venetoclax in AML/MDS), but these are Phase 1/1b and Phase 1/2 studies, not pivotal registrational trials. For a diversified giant like BMS, Onureg is a minor product grouped under "Other Growth Brands" and is unlikely to drive material share-price movement on its own.

Price Chart

Loading chart...

Executive Summary

Onureg (oral azacitidine, CC-486) is an already-approved, commercially marketed drug from Bristol Myers Squibb (BMY) for maintenance treatment of adults with acute myeloid leukemia (AML) in first remission. It was FDA-approved on September 1, 2020 based on the Phase 3 QUAZAR AML-001 trial, which showed a nearly 10-month overall survival benefit over placebo. An FDA efficacy supplement (s003) was approved in April 2026 updating the label. Onureg is a small product within BMS's diversified ~$50B annual revenue portfolio, grouped under "Other Growth Brands" without individually reported revenue. The drug faces eventual generic competition as patents begin expiring around 2029-2030, and a Paragraph IV challenge has been filed. Ongoing early-stage trials explore combinations with venetoclax in AML and MDS, but no pivotal readout or regulatory decision is imminent.

How It Works

Onureg is an oral tablet form of azacitidine, a chemotherapy drug that works by interfering with the DNA and RNA of rapidly dividing cancer cells. It is a hypomethylating agent, meaning it helps reactivate genes that can suppress tumor growth. Unlike the injectable version of azacitidine (Vidaza), Onureg can be taken at home as a pill.

Trial Status

Onureg was approved based on the Phase 3 QUAZAR AML-001 trial (NCT01757535), which demonstrated significant overall survival and relapse-free survival benefit versus placebo. The drug is commercially marketed. Ongoing early-stage trials are exploring Onureg in combination with venetoclax for AML (Phase 1/1b, NCT04887857, completed) and higher-risk MDS (Phase 1/2, NCT05782127, recruiting). A hepatic impairment study (NCT05209295) was terminated.

The Two-Sided Case

▲ Bull Case4
Onureg is the first and only FDA-approved oral maintenance therapy for AML patients in first remission, offering a convenient at-home alternative to injectable azacitidine.
The pivotal QUAZAR AML-001 trial showed a clinically meaningful nearly 10-month overall survival benefit (24.7 vs 14.8 months) versus placebo, providing strong efficacy data.
EMA approval in Europe (June 2021) and ongoing combination trials with venetoclax could expand the addressable market into earlier lines and MDS.
Onureg is part of BMS's 'Growth Portfolio,' which grew 12% in Q3 2026, and BMS raised its full-year 2026 revenue guidance, reflecting overall portfolio strength.
▼ Bear Case4
Onureg is a minor product for BMS, grouped under 'Other Growth Brands' with no individually reported revenue, meaning even strong sales growth has negligible impact on a ~$50B revenue company.
Generic injectable azacitidine already exists, and Dr. Reddy's launched a generic version in the U.S. in 2024, pressuring pricing. Oral azacitidine patents begin expiring around 2029-2030, with generic entry estimated around June 2030.
The addressable patient population is narrow: only older AML patients in first remission who cannot undergo stem cell transplant, limiting peak revenue potential.
A Paragraph IV patent challenge has been filed against Onureg, creating overhang on long-term exclusivity.

Upcoming Catalysts

  • No upcoming PDUFA, pivotal readout, or regulatory decision identified for Onureg in the next ~12 months.
  • Data from the Phase 1/2 trial of Onureg + venetoclax in higher-risk MDS (NCT05782127) could emerge, but this is an early-stage, dose-finding study, not a registrational trial.
  • Patent litigation outcomes related to the Paragraph IV challenge could affect generic entry timing.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 13

Hover a chip for the title
1 news.bms.com2 accessdata.fda.gov3 accessdata.fda.gov4 ema.europa.eu5 bms.com6 bms.com7 drugpatentwatch.com8 pharsight.greyb.com9 nejm.org10 bioplayground.com11 packageinserts.bms.com12 reuters.com13 clinicaltrials.gov